CyberKnife? Prostate SBRT Outcomes and Quality of Life Data Presented at American
Urological Association Meeting
Long Term Outcomes for Intermediate-Risk Prostate Cancer Patients
SUNNYVALE, Calif., June 7, 2012 /PRNewswire via COMTEX/ -- SUNNYVALE, Calif.,
June 7, 2012 /PRNewswire/-- Accuray Incorporated (ARAY), the premier radiation
oncology company, announced today that outcome data on intermediate risk prostate
cancer patients treated with CyberKnife? Prostate SBRT was presented at the
American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga. The
prospective monotherapy study, titled, "Four Year Outcomes and Quality of Life
Following Stereotactic Body Radiation Therapy: A Rapid, Non-Invasive Alternative
for the Treatment of Intermediate-Risk Organ Confined Prostate Cancer," expands
upon prior studies to further evaluate the long term efficacy and quality of life
outcomes from treatment with CyberKnife stereotactic body radiation therapy
(SBRT) for intermediate-risk prostate cancer patients. The study found a 91
percent biochemical control rate at four-years, which is comparable to both
surgical and non-surgical treatments for intermediate risk prostate cancer
patients, while demonstrating similar to improved toxicity outcomes.
The study consisted of 81 intermediate-risk organ confined prostate patients
treated by Dr. Alan Katz at Winthrop University Hospital with a median follow-up
of four years including 24 patients with a minimum of five years follow up. This
study showcases the long term published data on the use of the non-invasive
CyberKnife SBRT five day course of treatment for intermediate-risk prostate
cancer. Most notably the study found a four-year relapse-free survival rate of 91
percent. Patients experienced mild toxicity with minimal impact on quality of
life and immediate to rapid return to normal activity. These results further
support the value of CyberKnife prostate SBRT to achieve high rates of long term
disease control while sparing healthy tissue and critical nearby structures,
thereby minimizing undesirable side effects typically associated with other
treatment modalities and preserving patients' quality of life.
"CyberKnife prostate SBRT offers patients a short five-day, non-invasive
treatment for organ confined prostate cancer," said Alan Katz, M.D., author of
the study, currently a radiation oncologist at Flushing Radiation Oncology.
"Based on our study results, patients with intermediate-risk prostate cancer have
an option for a less invasive alternative to invasive surgery or six to eight
weeks of conventionally fractionated radiation therapy, that effectively and
efficiently treats their cancer, while preserving their overall quality of life."
"This study represents positive long term outcomes of CyberKnife SBRT for
intermediate-risk prostate patients, further supporting the value of this patient
centric technique," said Omar Dawood, M.D., M.P.H., senior vice president of
global medical affairs for Accuray. "These results add to the rapidly maturing
strong foundation of published clinical evidence for CyberKnife prostate SBRT and
further support the need to create head to head evidence to compare outcomes of
this treatment with surgery and conventionally fractionated radiation treatments
as is underway in the recently launched PACE study. We look forward to the
outcomes of the PACE study, which aims to build upon these results and further
support CyberKnife SBRT as a potential gold standard for the treatment for
patients with organ confined prostate cancer."
About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the
premier radiation oncology company that develops, manufactures and sells
personalized innovative treatment solutions that set the standard of care, with
the aim of helping patients live longer, better lives. The Company's leading edge
technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver
radiosurgery, stereotactic body radiation therapy, intensity modulated radiation
therapy, image guided radiation therapy, and adaptive radiation therapy. To date
635 systems have been installed in leading hospitals around the world. For more
information, please visit accuray.com.  |
